Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.

Ann Thorac Med 2017 Oct-Dec;12(4):294-297

Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA.

There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide for the treatment of interstitial lung diseases (ILDs) associated with systemic sclerosis (SSc). However, no report has addressed its efficacy in Saudi patients with SSc-ILD. To assess the efficacy of RTX treatment in Saudi patients with SSc-ILD, hospital records were reviewed between 2013 and 2016. Four female patients received at least 4 cycles of RTX (I cycle, consisting of two infusions of 1000 mg 2 weeks apart). Pulmonary function tests (PFTs) and chest high-resolution computed tomography (HRCT) were performed before and after treatment to assess the response. HRCT revealed improvement in one patient, stable disease in two patients, and worsening in one patient. Moreover, RTX prevented the further decline of forced vital capacity significantly in PFT. These results provide further evidence that RTX is an effective treatment for SSc-ILD.

Download full-text PDF

Source
http://dx.doi.org/10.4103/atm.ATM_30_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656950PMC
November 2017
6 Reads

Publication Analysis

Top Keywords

saudi patients
8
systemic sclerosis
8
interstitial lung
8
patients ssc-ild
8
patients
5
rtx
5
apart pulmonary
4
weeks apart
4
pulmonary function
4
tests pfts
4
computed tomography
4
tomography hrct
4
high-resolution computed
4
chest high-resolution
4
1000 weeks
4
pfts chest
4
function tests
4
cycle consisting
4
2016 female
4
2013 2016
4

Similar Publications

Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.

Rheumatology (Oxford) 2015 Aug 3;54(8):1420-8. Epub 2015 Mar 3.

Institute of Clinical Medicine, Department of Rheumatology.

Objective: To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD).

Methods: Patients with severe ILD and >12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Read More

View Article
August 2015

Interstitial lung disease in systemic sclerosis.

Autoimmun Rev 2011 Mar 21;10(5):248-55. Epub 2010 Sep 21.

Université Paris Descartes, Institut Cochin, Inserm U1016, Paris, France.

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up to 75% of patients with SSc overall. However, SSc-ILD evolves to end-stage respiratory insufficiency in only a few patients. Read More

View Article
March 2011

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Rheumatology (Oxford) 2010 Feb 15;49(2):271-80. Epub 2009 May 15.

Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504 Rion, Patras, Greece.

Objective: To assess the efficacy of rituximab (RTX) in SSc.

Methods: Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Read More

View Article
February 2010

Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.

Clin Rheumatol 2016 Sep 23;35(9):2339-45. Epub 2016 Apr 23.

Autoimmune Systemic Diseases Unit Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.

This study aims to evaluate the utility of magnetic resonance imaging (MRI) to assess interstitial lung disease (ILD) extent in patients with systemic sclerosis (SSc). Patients with SSc and varying degrees of ILD with a high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and a chest MRI containing an ultrafast SE sequence performed less than 1 year apart were included in the study. Wells global disease extent and Goh's staging algorithm were used to measure and categorize ILD both for MRI and HRCT. Read More

View Article
September 2016